Biosidus boosts agalsidase beta production with new Argentine bioreactor plant
Executive summary: Biosidus announced the launch of a new bioreactor plant in Argentina to increase production capacity for agalsidase beta, the enzyme replacement therapy for Fabry disease. The expansion aims to strengthen global supply of a critical therapeutic, addressing growing patient demand for Fabry disease enzyme replacement.
Who is involved: Biosidus (Argentina), its manufacturing team, and relevant health regulators (e.g., ANMAT, FDA/EMA) overseeing biologic product approvals.
Likely next: Completion and validation of the new bioreactor facility, followed by scale‑up of production and potential regulatory filings to support increased supply.
Biosidus, an Argentine biotech with over four decades of experience in biosimilars, announced the launch of a new bioreactor facility to increase manufacturing capacity for agalsidase beta, the enzyme replacement therapy for Fabry disease. The expansion aims to strengthen the company's global supply chain and respond to rising patient demand. While the announcement lacks specific capacity figures or timelines, it signals Biosidus' commitment to scaling up production of a critical therapeutic.
Timeline
- — Biosidus расширяет мощности по производству биопрепаратов и укрепляет глобальные возможности поставок агалсидазы бета (PR Newswire)
- — AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease (PR Newswire)
- — TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO‑PRIMARY AND ALL KEY SECONDARY ENDPOINTS (PR Newswire)
Analysis — what this means
Sectors affected
- enzyme replacement therapy (ERT) for Fabry disease
- biopharmaceutical manufacturing
Sources
- Biosidus расширяет мощности по производству биопрепаратов и укрепляет глобальные возможности поставок агалсидазы бета — PR Newswire
- AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease — PR Newswire
- TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO‑PRIMARY AND ALL KEY SECONDARY ENDPOINTS — PR Newswire